Europe & Asia
phone: +49 (0)941 942 76-100
fax:        +49 (0)941 942 76-780
US & Canada
phone:+1-877-720-GENE (4363)
fax:       +1-416-233-0854

Proprietary GENEART Production Process

GENEART’s optimization and production processes are protected by a large portfolio of own patents, patent applications and in-licensed third parties’ intellectual property rights.

Gene Optimization:

  • German patent application No. 10 260 805, and foreign patent applications pending under WO2004059556: Method and devices for optimizing a nucleotide sequence for the purpose of expression of a protein
  • License from The General Hospital Corporation, d/b/a Massachusetts General Hospital, to make, use and sell products and processes under U.S. Patent 6,114,148 “High level expression of proteins” and to grant to its customers the right to use products purchased from GENEART and falling under this patent for internal research and development purposes
  • License from The General Hospital Corporation, d/b/a Massachusetts General Hospital, to make, use and sell products and processes under U.S. Patent 5,786,464, EP 0781329 and CA 2,200,342 “Overexpression of mammalian and viral proteins” and to grant to its customers the right to use products purchased from GENEART and falling under these patents for internal research and development
  • German patent application No. 10 2004 037 652, and foreign patent applications pending under WO2006015789: Method for modulating gene expression by modifying the CpG content


Gene Synthesis, Variant and Library Construction:

  • U.S. Patent No. 6,472,184: Method for producing nucleic acid polymers
  • License from City of Hope to use the primer extension process to manufacture and sell DNA molecules under US Patent No. 5,750,380
  • License from F. Hoffmann-La Roche Ltd. to practice the polymerase chain reaction process (PCR) to manufacture in Germany and to sell worldwide DNA molecules (European Patent Nos. 0 200 362 and 0 201 184, United States Patent Nos. 4.683.195 and 4.683.202)
  • European Patent No. 1 913 140, German Patent No. 10 2005 037 351, and foreign patent applications pending under WO07017229: Method for carrying out the selective evolution of proteins in vitro
  • European Patent No.1 913 139, German patent application No. 10 2005 037 349, and foreign patent applications pending under WO07017228: Methods for carrying out the selective evolution of proteins in vivo
  • German Patent No. 10 2007 057 802, and foreign patent applications pending under WO09068305: Steganographic embedding of information in coding genes
  • German Patent No. 10 2007 052 344, German patent application No. 10 2009 011 253.7, and foreign patent applications pending under WO09056343: Method for determining frameshift mutations in coding nucleic acids


Subcloning & other Technologies:

  • License of Invitrogen IP Holdings Inc. to use the Gateway® technology under U.S. Patent Nos. 5,888,732, 6,143,557, 6,171,861, 6,270,969, 6,277,608, and 6,720,140, and / or other pending U.S. and foreign patent applications owned by Invitrogen Corporation
  • License of EMD Chemicals Inc. for pTriEx™ 1.1 vector under U.S. Patent Nos. 6,589,783 and/or other pending U.S. and foreign patent applications owned by EMD Chemicals Inc.
  • License of Dyax Inc. to practice the bacteriophage display inventions (U.S. Patent Nos. 5,223,409, 5,403,484, 5,571,698, 5,837,500 and / or other pending U.S. and foreign patent applications) for sale of a SH3 phage display library and for funded customer research  
  • German Patent No. 100 53 781, European Patent No. 1 356 111, and foreign patent applications pending under WO0236791: Nucleus export reporter system
  • European Patent No. 1 240 333, U.S. Patents No. 7,332,588 and 7,323,557, German patent application No. 100 56 747, and foreign Patents and patent applications pending under WO0136614: The genome of the HIV-1 intersubtype (C/B’) and use thereof
  • European Patents No. 1 156 112, 1 282 712, U.S. Patent No. 7,378,515, and foreign Patents and patent applications pending under WO0188141: Synthetic gagpol genes and their uses
  • German patent application No. 10 2004 037 611, and foreign patent applications pending under WO06013103: Inducible gene expression
Print PDF